Incorporation of Thalidomide into Up-Front Double Autologous Stem-Cell Transplantation (ASCT) for Multiple Myeloma Improves the Outcome in Comparison with Double ASCT without Thalidomide. Analysis of Baseline Factors Predicitve of Outcome.Elena Zamagni, Michèle Cavo, Patrizia Tosi et al.|Blood|2007Cited by 3
Incorporation of Thalidomide-Dexamethasone (Thal-Dex) into up-Front Double Autologous Stem-Cell Transplantation (ASCT) for multiple Myeloma: Final analysis of phase II “Bologna 2002” Study.Elena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Blood|2009Cited by 1
Final analysis of the multicenter phase II "Bologna 2002" study incorporating thalidomide-dexamethasone (thal-dex) into up-front double autologous stem-cell transplantation (ASCT) for multiple myelomaElena Zamagni, Michèle Cavo, Nicoletta Testoni et al.|Unknown|2009Cited by 0